Archeus Technologies and Wisconsin Alumni Research Foundation Partner to Advance Radiopharmaceutical Therapy ART-101 into Clinical Development for Prostate Cancer
MADISON, Wis.--(BUSINESS WIRE)-- Archeus Technologies, a company developing multiple differentiated radiopharmaceutical therapies, and the Wisconsin Alumni Research Foundation (WARF), the patenting and licensing arm of the University of Wisconsin–Madison (UW), today announced a strategic collaboration to advance ART-101 – a promising receptor-based targeting molecule – into clinical development.
ART-101 was discovered and developed at the Advanced Radiotheranostics Lab at UW–Madison, led by Dr. Reinier Hernandez, assistant professor of medical physics at the University of Wisconsin School of Medicine and Public Health. Aided by robust support from WARF through the WARF Accelerator, ART-101 has demonstrated enhanced pharmacology in preclinical studies, including significantly higher tumor uptake and retention relative to FDA-approved prostate cancer treatment Pluvicto ® (177Lu-PSMA-617). It has also shown superior pharmacokinetics, dosimetry and normal tissue toxicity profiles.
Through a collaboration agreement with WARF, Archeus Technologies will lead Phase 1 clinical development of this asset with trial initiation planned for 2025. ART-101 is a next-generation prostate-specific membrane antigen (PSMA)-targeting small molecule. It is being evaluated as a radiopharmaceutical agent with the potential to deliver alpha-emitting isotopes with greater tolerability compared with current standards of care.
'With strong preclinical data supporting the continued development of ART-101, Archeus is eager to lead the evaluation of this novel candidate through first-in-human studies,' said Evan Sengbusch, Ph.D., chief executive officer of Archeus Technologies. 'Leveraging our team's proven experience ushering new radiopharmaceutical agents from concept through clinical translation, paired with our close collaboration with UW as a world-class radiopharmaceutical research organization, Archeus is uniquely positioned to progress ART-101 into the next stage of development. This asset adds to our Phase 1-ready portfolio of differentiated radiopharmaceutical therapies with the potential to provide curative responses to cancers that are particularly challenging to treat.'
'WARF is committed to investing in cutting-edge technologies and therapeutic candidates, like ART-101, that have significant potential to advance the theranostics landscape as well as treatment options for patients in need,' said Jeanine Burmania, senior director of intellectual property and licensing at WARF. 'Encouraging preclinical data suggest that ART-101 could help increase lifespan and be more effective in treating prostate cancer than current therapies. We're pleased to partner with Archeus Technologies to continue the development of this innovative asset and look forward to better understanding its role to potentially improve outcomes for prostate cancer patients.'
ART-101 is compatible with multiple therapeutic isotopes, including actinium-225, lutetium-177 and terbium-161. When paired with these isotopes, preclinical data show that ART-101 provides significant potential benefit that could lead to improved outcomes for prostate cancer patients.
About Archeus Technologies
Archeus Technologies is a company developing differentiated radiopharmaceutical therapies for some of the most difficult-to-treat cancers. Starting with its Phase 1-ready therapeutic candidate, ARC-706, the company has assembled a growing pipeline of novel radiopharmaceutical therapy agents and companion diagnostic assets with the potential to provide curative responses to patients with advanced disease. Archeus is led by an executive team with proven radiopharmaceutical expertise and a demonstrated record of advancing innovative agents from discovery through clinical development. In addition, Archeus has a long-standing strategic collaboration with the University of Wisconsin-Madison (UW), a global leader in radiopharmaceuticals and theranostics. To learn more, visit ArcheusTech.com.
About WARF
Celebrating a century of service in 1925, the Wisconsin Alumni Research Foundation (WARF) patents and licenses discoveries from UW-Madison research, manages an investment portfolio generated from licensing and investment proceeds, and provides annual grants to the University of Wisconsin-Madison and the Morgridge Institute for Research to support further scientific investigation and research. By driving collaborations among researchers, investors, industry and entrepreneurs, WARF commercializes innovations from campus through various initiatives. WARF Accelerator improves the commercialization potential of university intellectual property through industry engagement and investment in proof-of-concept milestones to validate market potential, demonstrate commercial value and de-risk technology. WARF Therapeutics partners with UW-Madison and Morgridge Institute researchers employing an industry-focused approach to improve the value propositions of drug candidates. WARF Ventures is an early-stage venture fund that invests in startups based on UW/WARF technologies. Learn more at warf.org.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
LithiumBank Updates NI 43-101 Lithium Brine Resource Estimate at Park Place, West-Central Alberta
Vancouver, British Columbia--(Newsfile Corp. - May 29, 2025) - LithiumBank Resources Corp. (TSXV: LBNK) (OTCQX: LBNKF) ("LithiumBank" or the "Company") is pleased to announce an update to the National Instrument 43-101 - Standards of Disclosure for Mineral Projects ("NI 43-101") resource estimate for the Park Place Lithium Brine Project ("Park Place"), located in west-central Alberta. The Company has made strategic reductions in the total holdings of brine hosted mineral licences ("BHML") at Park Place (Figure 1 & Table 2) in an effort to focus on areas that have the highest potential rates of brine production based on three-dimensional ("3D") static reservoir modelling (see news release dated June 24, 2024). The updated BHML holdings for Park Place consist of 226,683 ha for a total of 15,082,000 tonnes inferred of Lithium Carbonate Equivalent ("LCE") at a grade of 80.0 mg/L lithium. The updated BHML position reduces the Company's annual licencing fees by C$821,468. The initial NI 43-101 compliant technical report for Park Place entitled "LithiumBank Resources Corp. Park Place NI 43-101 Technical Report" effectively dated June 24, 2024, prepared by the following Qualified Persons: Alex Haluszka P. Geo. of Montrose Environmental Solutions Canada Inc., Mr. Maurice Shevalier, of Montrose Environmental Solutions Canada Inc. and Mr. Roy Eccles P. Geol. of APEX Geoscience Ltd., originally reported 21,681,000 tonnes of inferred LCE at a grade of 80.2 mg/L lithium (Table 1) (see news release dated June 24, 2024) and is available on SEDAR+. The updated NI 43-101 resource estimate for Park Place, based on the Company's current holding of BHMLs, totals 15,082,000 tonnes of inferred LCE at a grade of 80.0 mg/L lithium (Table 1) within contiguous BHMLs (Figure 1). The Company focused on maintaining the core Park Place asset where the Leduc formation ("Fm") and the Swan Hills Fm are stacked and offer the most favourable potential for long-term lithium-rich brine production. No additional technical data has been collected or identified and thus the reduction in the resource estimate is purely due to the reduced footprint of the BHMLs. The Company elected not to renew approximately 50% of the Park Place BHMLs, based on reservoir quality and potential production capacity, totalling 234,705 ha of BHMLs that have now expired. The Company now holds a strategic position of 226,683 ha at Park Place. The Company also allowed the non-core portion, approximately 50%, of the Peace lithium brine project to expire (Table 2). Park Place Resource Estimate Highlights include: Park Place continues to be one of the largest known NI 43-101 inferred lithium brine resource estimates in North America with 15,082,000 tonnes inferred LCE. Park Place has the second highest reported lithium-in-brine grades used in a NI 43-101 compliant inferred lithium resource estimate in Alberta at 80.0 mg/L lithium. Second only to the Company's Boardwalk lithium brine project (Figure 1). 8,659,000 tonnes inferred LCE within the Leduc Fm aquifer at an average of 79.4 mg/L lithium. 6,423,000 tonnes inferred LCE within the Swan Hills Fm aquifer, which underlies the Leduc Fm, at an average of 80.9 mg/L lithium. Multiple high porosity areas occur that have a combined Leduc & Swan Hills Fm thickness of over 350 metres, and as high as 511 m, to be studied for potential selection of future preliminary economic assessment ("PEA"). Subsurface reservoir modelling conducted by SLB and Montrose included data from 420 wells, 104 km2 of 3D seismic data and 262 km of two-dimensional seismic data. The subsurface reservoir model will assist in planning well networks and locations in future economic and engineering studies such as a PEA. Park Place bulk brine sample collection (35,000L) returned >95% lithium recovery and over 99% impurity removal from the direct lithium extraction pilot testing with SLB/ILiAD (see news released April 14, 2025). Reporting Parameters Original Leduc Fm Domain Original Swan Hills Fm Domain Original Combined Total Updated Leduc Fm Domain Updated Swan Hills Fm Domain Updated Combined Total Total Volume (km3)1 501.2 660.5 1,161.70 422.1 366.7 788.80 Pore Volume (km3)2 25.1 28.4 53.5 21.6 15.7 37.3 Average Li Concentration (mg/L) 79.4 80.9 80.23 79.4 80.9 80.03 Average Effective Porosity (%) 5 4.3 4.64 5 4.3 4.74 Average Brine Pore Space (%) 95 95 95 95 95 95 Total Elemental Li (tonnes) 1,893,000 2,183,000 4,076,000 1,627,000 1,207,000 2,834,000 Total LCE (tonnes) 10,076,000 11,620,000 21,697,000 8,659,000 6,423,000 15,082,000 Table 1: Park Place updated NI 43-101 resource estimate compared to the original resource estimate. 1. Total volume of rock and pore space2. Total volume of effective porosity3. Calculated using a weighted average (by pore volume) from the average grade of the Leduc and Swan Hills formations4. Calculated using a weighted average porosity by total formation volume for both Leduc and Swan Hills formationsNotes1: Mineral resources are not mineral reserves and do not have demonstrated economic viability. There is no guarantee that all or any part of the mineral resource will ever be upgraded to a higher category. The estimate of mineral resources may be materially affected by geology, environment, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues.2: The weights are reported in metric tonnes (1,000 kg or 2,204.6 lbs).3: Tonnage numbers are rounded to the nearest 1,000 unit.4: In a 'confined' aquifer (as reported herein), effective porosity is an appropriate parameter to use for the resource estimate.5: The resource estimation was completed and reported using a cut-off of 50 mg/L Li.6: To describe the resource in terms of industry standard, a conversion factor of 5.323 is used to convert elemental Li to Li2CO3, or Lithium Carbonate Equivalent (LCE). The consolidated Park Place project consists of 538,360 acres of contiguous BHMLs. Park Place is situated between Edson, Fox Creek, and Hinton, approximately 180 km west of Edmonton, and is approximately 50 km to the south of the Company's Boardwalk lithium brine project ("Boardwalk"). This area has seen over 70 years of hydrocarbon extraction resulting in a well-established and well-trained labour force, networks of all-weather gravel roads, drill sites that can be easily accessed from Provincial highways, and electrical transmission lines that run through and adjacent to the project (see Figure 1). The Swan Hills Fm directly underlies the Leduc Fm and appear to be in hydraulic communication based on regionally available pressure data. While they may represent a regionally connected aquifer system, the two formations are evaluated separately due to an identifiable difference in lithology and porosity. The Swan Hills Fm is mapped to from 24 to 264 m in thickness within the claims area and the Leduc Fm immediately overlies the Swan Hills Fm, where present, with a maximum thickness of 366 m within the claims area. The maximum observed combined thickness where the two units overlap within the property is 511 m of highly porous reservoir rock occur that would potentially present ideal locations for consideration in an economic assessment. Table 2. LithiumBank BHML holdings before and after reduction. Alberta Projects BHML Holding Before Reduction (hectares) Current BHML Holding (hectares) BHML Change (hectares) Boardwalk 159,979 159,979 0 Park Place 461,388 217,866 -243,522 Peace 29,500 13,920 -15,580 Total Alberta Holdings 650,867 400,582 -250,285 Figure 1: Map of the Park Place and Boardwalk projects highlighting categories of NI 43-101 lithium brine resource estimates. To view an enhanced version of this graphic, please visit: Additionally, further to the Company's news release dated September 11, 2023, the Company announces that effective May 28, 2025, LithiumBank and G2L Greenview Resources Inc. ("G2L") have mutually agreed to terminate their intellectual property license agreement, technology services agreement and all related statements of service (collectively, the "Agreements"). The parties each entered into a full release agreement confirming there are no further obligations on behalf of either LithiumBank or G2L in respect of the Agreements. The termination reflects a strategic realignment by both parties to pursue independent opportunities aligned with their respective technology and commercialization priorities. The scientific and technical information relating to the mineral resource estimate presented in this news release has been reviewed and approved by Alex Haluszka P. Geo. of Montrose Environmental Solutions Canada Inc., Alex Haluszka is independent of LithiumBank and a Qualified Person as defined by NI 43-101. About LithiumBank Resources Corp. LithiumBank Resources Corp. (TSXV: LBNK) (OTCQX: LBNKF), is a publicly traded lithium company that is focused on developing its two flagship projects, Boardwalk and Park Place, in Western Canada, which host some of the largest lithium brine resources in North America (Figure 3). The Company holds 1,237,487 acres of brown-field brine hosted mineral licenses, across three (3) districts in Alberta and Saskatchewan. The Company has pilot tested multiple mature Direct Lithium Extraction ("DLE") technologies and is working toward establishing commercial lithium production by a modular approach. Contact:Rob Shewchuk CEO & Directorrob@ (778) 987-9767 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding Forward-Looking Statements This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including without limitation, the Company's expectations regarding the usefulness of subsurface reservoir models in planning well networks and locations in future economic and engineering studies. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should" or "would" or occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the subsurface reservoir model conducted by SLB and Montrose will assist the Company in planning well networks and locations in future economic and engineering studies. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that the subsurface reservoir model conducted by SLB and Montrose will not assist the Company in planning well networks and locations in future economic and engineering studies. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference
PALO ALTO, Calif., May 29, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth, M.D., Chief Executive Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City, NY on Thursday, June 5, 2025, at 9:20am ET (6:20am PT). A live webcast of the presentation will be available on the "Events and Presentations" section of Kodiak's website at and will remain available for replay for a limited time following the event. About Kodiak Sciences Inc. Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing, and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform® uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's maturing pipeline includes three late-phase clinical assets, all three targeting Phase 3 topline data in 2026. For more information, please visit Kodiak®, Kodiak Sciences®, ABC®, ABC Platform®, ABCD™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions. View original content: SOURCE Kodiak Sciences Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Anal Cancer Market Heats Up Following Incyte's Zynyz Greenlight
Several companies are advancing treatments for anal cancer, including Merck (KEYTRUDA), BioMimetix (BMX-001), Novartis (KFA115), and Bicara Therapeutics (BCA101), among others. As immunotherapy and targeted therapies gain traction, competition will increase, raising the bar for efficacy and safety. The market is shifting toward personalized, less toxic treatments, creating opportunities for novel entrants but demanding strong differentiation. LAS VEGAS, May 29, 2025 /PRNewswire/ -- Anal cancer is relatively uncommon, accounting for approximately 2.5% of all gastrointestinal cancers. Nonetheless, its incidence has been gradually increasing over the past 30 to 40 years. The disease is more frequently diagnosed in women than in men and typically affects individuals between the ages of 45 and 75. Anal squamous cell carcinoma (ASCC) is the predominant type, comprising around 80–85% of anal canal cancer cases. Less frequent forms include adenocarcinomas, melanomas, and basal cell carcinomas. According to DelveInsight's analysis, there were around 20,000 new cases of anal cancer across the seven major markets in 2023, a figure projected to rise by 2034. In the United States, approximately 82% of anal cancer cases were linked to HPV, underlining it as the primary cause. Combination chemoradiotherapy (CRT) is the standard first-line treatment for locoregional anal cancer. However, an exception is made for early-stage perianal tumors that do not involve the anal sphincter and for superficially invasive squamous cell carcinoma (SCC) of the anus, where wide local excision may be appropriate. The treatment approach for anal cancer has evolved from surgery to combined chemoradiation, enabling preservation of anal function. Despite trials investigating induction chemotherapy, maintenance therapy, and planned treatment breaks, the established standard remains a combination of mitomycin C (MMC), 5-fluorouracil (5-FU), and radiotherapy (RT) without these additional modifications. In recent years, intensity-modulated radiotherapy (IMRT) has replaced older radiotherapy methods and is now considered standard practice. Current research efforts also aim to reduce radiation-related side effects, with bone marrow-sparing IMRT emerging as a promising technique to limit hematologic toxicity. While immunotherapy is currently recommended as a second-line option for metastatic disease, its role is being actively explored in the locoregional setting. In particular, immune checkpoint inhibitors (ICIs) have garnered significant attention in recent studies involving patients with locoregional squamous cell carcinoma of the anus (SCCA). Learn more about the anal cancer treatment @ New Treatment for Anal Cancer Incyte's PD-1 inhibitor Zynyz has re-emerged in the treatment of anal cancer following two concurrent FDA approvals, marking a significant turnaround four years after its initial rejection. In May, 2025, the FDA approved Zynyz, a humanized monoclonal antibody targeting PD-1, for use alongside carboplatin and paclitaxel as a first-line therapy for adults with inoperable, locally recurrent, or metastatic squamous cell carcinoma of the anal canal (SCAC). In addition, Zynyz received approval as a monotherapy for adults with locally recurrent or metastatic SCAC who have either progressed on or are unable to tolerate platinum-based chemotherapy. Previously approved in 2023 for treating metastatic, recurrent, or locally advanced Merkel cell carcinoma, Zynyz has now become a cornerstone of Incyte's oncology pipeline. Its latest approval follows a Priority Review of a supplemental Biologics License Application (sBLA), backed by data from two clinical trials: the Phase III POD1UM-303/InterAACT2 and the Phase II POD1UM-202 studies. The Phase III POD1UM-303/InterAACT2 trial evaluated Zynyz in combination with carboplatin and paclitaxel in patients with metastatic or inoperable, locally recurrent SCAC who had not previously received systemic chemotherapy. The Phase II POD1UM-202 trial focused on Zynyz as a standalone therapy for patients with advanced SCAC who had relapsed after or were intolerant to platinum-based regimens. The intravenous monotherapy approval was based on results from POD1UM-202, which demonstrated a 14% objective response rate (ORR) and a 49% disease control rate. The safety profile was consistent with expectations for PD-1 inhibitors and showed no negative impact on HIV management in infected patients. Serious adverse events occurred in 40% of patients, with the most common (≥2%) including infections (excluding urinary tract), abdominal and perineal pain, anemia, bleeding, diarrhea, fever, urinary tract infections, musculoskeletal pain, and respiratory symptoms. Find out more on FDA-approved anal cancer drugs @ Anal Cancer Treatment Options Alongside the US submission, Incyte has also filed a Type II variation Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) and a Japanese New Drug Application (J-NDA) with the Pharmaceuticals and Medical Devices Agency (PMDA) for retifanlimab in advanced SCAC. Both applications are currently under review. The approval of Zynyz has heightened competition among pharmaceutical players such as Merck, BioMimetix, Novartis, and Bicara Therapeutics, pushing them to fast-track the development of their flagship drug candidates to gain market share and challenge Incyte's foothold. Discover which therapies are expected to grab major anal cancer market share @ Anal Cancer Market Report Merck is advancing its blockbuster PD-1 inhibitor, KEYTRUDA, which is currently in Phase II trials. Upon approval, it is expected to directly rival Incyte's Zynyz in the anal cancer treatment space. Zynyz (retifanlimab) could soon face competition not only from other PD-1 inhibitors but also from innovative therapies beyond this class. A notable example is BioMimetix's BMX-001, a redox-active metalloporphyrin (MnP) small molecule known for its strong anti-inflammatory effects. BMX-001 acts through a dual mechanism that affects both tumor and healthy tissues. In cancer cells, it inhibits critical signaling pathways such as NF-κB and HIF-1α, which are key to inflammation, angiogenesis, and tumor survival. This inhibition supports cancer cell death, reduces blood vessel formation, and curtails long-term tumor growth. BioMimetix is currently enrolling patients in a Phase I/II clinical trial involving newly diagnosed anal cancer cases. Other emerging anal cancer treatments include Novartis' immunomodulator KFA115 and Bicara Therapeutics' bifunctional antibody BCA101, which targets both EGFR and TGFβ pathways. Discover more about drugs for anal cancer in development @ Anal Cancer Clinical Trials Overall, the anal cancer therapeutic pipeline appears robust, with a variety of innovative strategies in development that could transform treatment paradigms and enhance patient outcomes. The anticipated launch of these emerging therapies for anal cancer are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the anal cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for anal cancer is expected to grow from USD 7 million in the 7MM in 2023 at a significant CAGR by 2034. The anal cancer market is witnessing steady growth, driven by rising incidence rates, increased awareness, and advancements in diagnostic and treatment options. HPV remains a major contributing factor, prompting the development of targeted therapies and preventive vaccines. Improved screening programs and the approval of novel immunotherapies are further fueling market expansion. Additionally, growing investments in oncology research are supporting innovation and long-term market potential. DelveInsight's latest published market report, titled as Anal Cancer Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the anal cancer country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The anal cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Incident Cases of Anal Cancer Gender-specific Cases Age-specific Cases Histology-specific Cases HPV Status-specific Cases Stage-specific Cases Line-wise Treated Cases The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM anal cancer market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this anal cancer market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the anal cancer market. Also, stay abreast of the mitigating factors to improve your market position in the anal cancer therapeutic space. Related Reports HPV16-Positive Head and Neck Squamous Cell Carcinoma HPV16-Positive Head and Neck Squamous Cell Carcinoma Market Insights, Epidemiology, and Market Forecast – 2034 report shows that the 7MM market size is predicted to rise from USD 750 million in 2023 at a significant CAGR by 2034 owing to the active participation of key companies, including Bristol Myers Squibb, Merck, Merus, Exelixis, ISA Pharmaceuticals, Regeneron Pharmaceuticals, PDS Biotechnology, BioNTech, Cue Biopharma, Immutep, Iovance Biotherapeutics, Inovio Pharmaceuticals, MedImmune, Nykode Therapeutics, RAPT Therapeutics, among others. Crohn's Disease Market Crohn's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report shows that the 7MM market size is predicted to rise from USD 10.7 billion in 2024 at a significant CAGR by 2034 owing to the active participation of key companies, including Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (Zeria Pharmaceutical), Gilead Sciences, Galapagos NV, Boehringer Ingelheim, Celgene (Bristol Myers Squibb), Eli Lilly and Company, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast, among others. Human Papillomavirus Market Human Papillomavirus Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HPV companies, including Inovio Pharmaceuticals, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Merck, Pattern Pharma, Nykode, Vaccibody A/S, among others. Human Papillomavirus Pipeline Human Papillomavirus Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HPV companies, including Inovio Pharmaceuticals, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Merck, Pattern Pharma, Nykode, Vaccibody A/S, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
